X4 Pharmaceuticals Inc (XFOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) has a cash flow conversion efficiency ratio of -0.134x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.79 Million) by net assets ($155.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of X4 Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
X4 Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how X4 Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
X4 Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of X4 Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of X4 Pharmaceuticals Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
YC Inox Co Ltd
TW:2034
|
0.044x |
|
Spear REIT Ltd
JSE:SEA
|
0.045x |
|
Village Farms International Inc
NASDAQ:VFF
|
0.028x |
|
Hangzhou Coco Healthcare Products Co.Ltd.
SHE:301009
|
-0.012x |
|
Paz Corp
SN:PAZ
|
-0.032x |
|
Shanxi Huayang New Material Co Ltd
SHG:600281
|
-0.449x |
|
HeidelbergCement India Limited
NSE:HEIDELBERG
|
0.064x |
|
Microtek International Inc
TW:2305
|
0.027x |
Annual Cash Flow Conversion Efficiency for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of X4 Pharmaceuticals Inc from 2015 to 2025. View XFOR share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $186.29 Million | $-85.62 Million | -0.460x | +92.22% |
| 2024-12-31 | $22.15 Million | $-130.90 Million | -5.910x | -212.91% |
| 2023-12-31 | $51.10 Million | $-96.51 Million | -1.889x | -81.40% |
| 2022-12-31 | $74.05 Million | $-77.10 Million | -1.041x | +5.41% |
| 2021-12-31 | $64.41 Million | $-70.91 Million | -1.101x | -36.25% |
| 2020-12-31 | $72.80 Million | $-58.82 Million | -0.808x | -117.26% |
| 2019-12-31 | $129.22 Million | $-48.05 Million | -0.372x | +68.40% |
| 2018-12-31 | $21.60 Million | $-25.42 Million | -1.177x | -147.89% |
| 2017-12-31 | $58.71 Million | $-27.87 Million | -0.475x | -136.69% |
| 2016-12-31 | $-16.72 Million | $-21.64 Million | 1.294x | -47.68% |
| 2015-12-31 | $-4.37 Million | $-10.82 Million | 2.473x | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more